Here is a detailed review of the most significant insider purchases and disposals reported for Wednesday, July 8, 2026. The filings cover transactions executed on July 6, 7 and 8, 2026, and include both open-market buys and sales carried out under pre-arranged trading arrangements.
Top buys
Mission Produce, Inc. (NASDAQ: AVO) - The largest reported purchase for the review period involved Globalharvest Holdings Venture Ltd., identified as a 10% owner of Mission Produce. On July 6, 2026, the entity acquired 650,415 shares of Mission Produce common stock for a total reported value of $8,279,782. The weighted average price for the block was $12.73 per share, with individual trade prices cited in the filing between $12.43 and $13.20 per share. Following the acquisition, Globalharvest Holdings Venture Ltd. directly owns 11,191,352 shares of Mission Produce common stock. At the time the filing was reported, Mission Produce was trading at $13.50, an approximate 8% gain over the prior week and modestly above the weighted-average purchase price.
Boundless Bio, Inc. (NASDAQ: BOLD) - Kevin Tang and Tang Capital Management LLC, described as a significant shareholder of Boundless Bio, increased their position via a series of purchases executed between July 6 and July 8, 2026. The reporting owners acquired a total of 57,210 shares, representing aggregate consideration of $141,864. Transaction prices ranged from $2.42 to $2.50 per share, with specific weighted-average tranches reported as follows: on July 6, 27,062 shares at a weighted-average price of $2.49 (individual prices $2.46 to $2.50); on July 7, 15,810 shares at a weighted-average price of $2.48 (individual prices $2.44 to $2.50); and on July 8, 14,338 shares at a weighted-average price of $2.46 (individual prices $2.42 to $2.48). At the time of the filing, Boundless Bio traded at $2.45, noted as being up more than 111% over the past year and trading near a 52-week high of $2.79 with an 87% advance over the prior six months.
Evommune, Inc. (NASDAQ: EVMN) - Arthur S. Kirsch, a director at Evommune, purchased 10,000 shares on July 7, 2026, at a weighted average price of $13.30 per share, for a total transaction value of $133,000. Individual prices in the reported buys ranged from $13.25 to $13.35. The filing notes that after the purchase, Mr. Kirsch, through a family trust, holds those 10,000 shares of Evommune common stock. The filing also states that the stock is trading near a 52-week low of $12.07 and is down roughly 60% from a 52-week high of $33.20. Mr. Kirsch is described as a trustee of the family trust and disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.
Palisade Bio, Inc. (NASDAQ: PALI) - Robert Baltera Jr., a director at Palisade Bio, reported purchases totaling $102,084 executed over July 6 and July 7, 2026. On July 6 Mr. Baltera Jr. purchased 20,000 shares at a reported weighted average price of $2.052 per share, with individual trade prices reported between $2.04 and $2.068. The combined transactions across the two days had weighted average prices within a band of $2.0348 to $2.052 per share.
Jewett Cameron Trading Co Ltd (NASDAQ: JCTC) - AJB Investment Fund II, LP, together with affiliated persons Adam J. Bradley and Melinda Bradley, who are each identified as 10% owners, acquired a total of 34,388 shares of JCTC common stock through open-market purchases reported on July 7 and July 8, 2026. The aggregate consideration for those purchases was $86,410, with per-share prices ranging from $2.485 to $2.5199. The filing notes the company’s stock was trading at $2.48 and references a year-over-year decline of 33% but also indicates momentum with strong recent returns.
Top sells
Rocket Lab Corp (NASDAQ: RKLB) - The most sizable sell-side disclosure in dollar terms involved Rocket Lab Chief Executive Officer Peter Beck. According to Form 4 filings, Mr. Beck sold a total of 3,275,779 shares of Rocket Lab common stock across July 6, 7 and 8, 2026, realizing proceeds of approximately $286.4 million. The shares were sold at weighted-average prices between $81.5895 and $101.5698 per share. The filings indicate the sales were executed automatically under a Rule 10b5-1 trading plan adopted by the Equatorial Trust on March 27, 2026. At the time the transactions were reported, Rocket Lab shares were trading at $83.34, down 17% over the week but showing a 113% return over the past year.
Dell Technologies Inc. (NASDAQ: DELL) - Multiple filings showed affiliated Silver Lake entities, as well as director Egon Durban, selling Class C Common Stock on July 6, 2026. One Form 4 disclosed sales amounting to approximately $29.9 million, involving 72,766 shares sold at prices spanning $405.36 to $418.49 per share. A separate related disclosure recorded additional sales by Silver Lake affiliates totaling roughly $25.9 million, comprising 63,204 shares sold at the same per-share price range. Those sales followed a conversion of 93,371 shares of Class B Common Stock into an equal number of Class C Common Stock shares; the filings remind that each Class B share is convertible into one Class C share at any time. The filings identify the shares as being indirectly held through Silver Lake Partners IV, L.P., and note Egon Durban’s role as a Co-CEO and Managing Member of Silver Lake Group, L.L.C., and that he is deemed a director of Dell by deputization. At the time of reporting, Dell’s stock was trading at $432, a 241% return over the past year, trading near its 52-week high of $469.47 and well above its 52-week low of $110.22. The filings also reference valuation metrics for Dell, noting a price-to-earnings ratio of 34.43 and a PEG ratio of 0.34.
RH (NYSE: RH) - Gary Friedman, Chairman and Chief Executive Officer of RH, reported the sale of 129,200 shares of RH common stock across July 6 to July 8, 2026. The aggregate consideration for those sales was approximately $20,668,230, with executed prices ranging from $154.7065 to $171.1086 per share. The filings detail daily breakdowns: on July 6, Mr. Friedman sold 39,271 shares at a weighted average price of $169.0369 and an additional 29,798 shares at a weighted average price of $170.07; on July 7, he sold 7,298 shares at an average price of $170.0635 and 395 shares at an average price of $171.1086. At the time of reporting, the stock was trading at $162.59, down 9% year-to-date and materially below a 52-week high of $257.
Snowflake Inc. (NASDAQ: SNOW) - Michael L. Speiser, a director at Snowflake, sold 46,681 shares of common stock on July 6, 2026, generating approximately $12,219,867 in proceeds. The reported sales were executed at prices between $253.861 and $263.912 per share and were carried out under a pre-arranged 10b5-1 trading plan adopted on December 27, 2024. The filings break out the ownership structures involved: 33,905 shares were sold that were held indirectly by a trust where Mr. Speiser serves as trustee - after the sale the trust reportedly holds 1,165,264 shares; 12,373 shares were sold from holdings indirectly owned by a limited partnership in which Mr. Speiser is trustee of the trust that acts as the partnership’s general partner - after the sale the limited partnership holds 415,120 shares; and 403 shares were sold directly by Mr. Speiser, leaving his direct holdings at 22,976 shares. Snowflake’s stock was reported trading at $261.31, showing a 19% year-to-date return and trading near a 52-week high of $285.
Context and takeaways
The filings in this reporting window span a range of company sizes and sectors, with notable activity in food distribution, biotechnology, small-cap industrials, consumer retail, cloud software and aerospace. The largest single buy was the multi-million dollar open-market purchase by a 10% owner in Mission Produce, while the largest single seller by dollar value was Rocket Lab’s CEO, disposing of more than 3.2 million shares under an established trading plan. Several directors and significant shareholders in smaller-cap biotech and agricultural-related stocks increased holdings via open-market purchases. On the sell side, several large transactions involved affiliated entities and leveraged stock conversions in coordination with secondary market sales.
These filings illustrate a mixture of strategic adding to positions by insiders in smaller-cap names and systematic, plan-driven sales by executives and affiliates at larger public companies. The reported transactions include both discretionary open-market purchases and sales executed under Rule 10b5-1 plans or related automated mechanisms, as disclosed in the filings.
Key points
- Globalharvest Holdings Venture Ltd. led reported purchases with a 650,415-share acquisition of Mission Produce (AVO) on July 6, 2026, valued at $8,279,782 at a weighted average price of $12.73 per share.
- Multiple insiders or affiliated owners increased positions in small-cap names: 57,210 shares in Boundless Bio (BOLD), 10,000 shares in Evommune (EVMN), 20,000 of PALI on July 6 among other PALI transactions, and 34,388 shares of JCTC acquired by related 10% owners.
- Large-scale sell-side activity included Rocket Lab CEO Peter Beck’s sale of 3,275,779 shares under a Rule 10b5-1 plan and significant Dell Class C share dispositions by Silver Lake affiliates and Egon Durban.
Risks and uncertainties
- Timing and motive for sales - Several large sales were executed under pre-arranged trading plans. Such automated plans can create substantial near-term selling pressure without reflecting a change in corporate outlook.
- Price volatility in smaller-cap names - The purchases reported in biotech and smaller public companies reflect activity in stocks with notable price swings, as illustrated by references to 52-week highs and lows in several filings.
- Concentration and ownership changes - Significant purchases by 10% owners and large disposals by affiliates can materially shift ownership stakes and voting dynamics, which may influence company decisions or market perception.
Monitoring insider transactions offers a view of how directors, executives and major shareholders are altering their positions, but these disclosures must be interpreted alongside other information. Purchases may indicate confidence by reporting owners, while sales can reflect a range of non-operational motivations including diversification and pre-existing trading arrangements. Investors should consider such activity as one data point among many.